We ran our full Track-A market intelligence pipeline on Condor before reaching out — leadership, platform, market sizing, competitive set, regulatory, financial, commercial, and customer base. This page is the table of contents for what we found, how we built it, and where the work goes next.
No pricing. No pitch deck. The briefing is yours either way — this is a working session and a conversation about whether a partnership makes sense for the next 18 months.
BioCreative ran the full Track-A intelligence pipeline on Condor, packaged the same way we deliver for paying clients. Every claim back-cites the dossier and source it came from. Yours either way.
$24M from Insight is rocket fuel and a pressure cooker simultaneously. The next 18 months decide whether Condor sets the category or shares it. Independent, source-traced intelligence is what makes those calls easier.
Most outbound leads with a deck. We lead with an artifact. If the briefing is useful, the next conversation is a working session. If it isn't, you keep the briefing and we move on — no obligation in either direction.
Layer 1 is a positioning framework you can hand to a board observer in 20 minutes. Layer 2 is six domain reports, ~8 pages each. Layer 3 is eight deep-research dossiers, every one cited and source-traced.
Independent modeling on the $2.27B (2025) → $7.28B (2035) clinical trial financial management market suggests two waves of consolidation: ERP platforms (Workday, NetSuite) acquiring clinical-vertical specialists ~2027–2028, and Big 4 firms building captive analytics. Condor's 18-month window to set the category is real.
~80% of biotech IPOs face material weakness findings in their first audit cycle. Condor's SOC 1/2 Type 2 + 21 CFR Part 11 readiness is a moat — but messaging today leads with AI features, not audit posture. Re-leading the homepage with compliance-first framing compounds with the CFO buyer.
Across the visible logo wall (Acadia, Adverum, Akero, Alumis, BridgeBio, Caribou, CG Oncology, Intellia, Madrigal, Solid Bio, Ventyx, etc.), Condor is already managing meaningful slices of $19B+ in R&D spend. That number, surfaced as a single hero metric, re-anchors the buyer from "startup tool" to "category infrastructure."
Today the platform sells into Finance. The Clinical Operations buyer (study finance, vendor oversight, accruals) sees ~50% of the same pain and almost none of the competitive coverage from Veeva or Medidata. That's a $400M+ TAM expansion without changing the product surface.
Medidata controls ~40% of CTMS share. PwC has already co-authored your white paper. A formal three-way reference architecture (Medidata operational + Condor financial + PwC implementation) eliminates Veeva's strongest counter-pitch and makes Condor the default selection for any new biotech deploying CTMS in 2026–27.
Pattern-matching on adjacent SaaS markets, the most likely moves are: (a) Veeva ships a finance-lite module priced into Vault Suite, and (b) a Big 4 firm white-labels a competitor offering. Both are defensible — but only if Condor's Q3 release sets the compliance + AI bar one notch above where the market expects.
The same SaaS principles Condor applies to clinical financial intelligence — APIs at every layer, audit trails end-to-end, deterministic outputs, source traceability — applied to the GTM intelligence layer. Multi-tenant where it should be, single-tenant where it has to be.
Parallel agents fan out across leadership, market, competitive, regulatory, financial, technology, commercial, and customer-base dimensions. Each agent is scoped, source-traced, and rate-limited.
Stack: Custom multi-agent framework on Anthropic Claude + OpenAI + Google Gemini, orchestrated through our Brain layerAgent traces are folded into domain reports by a long-context model that pressure-tests claims, surfaces contradictions, and back-cites every line.
Stack: Gemini 2.x for long-context synthesis · Claude Sonnet for refinement & judgingWe map the live buyer graph around each prospect — the actual people, titles, companies, and signals that make up the addressable market — before any outreach is written. Already started for Condor's orbit.
Stack: LinkedIn Sales Navigator · Clay enrichment · BioCreative's life-sciences contacts databaseDeterministic data feeds — clinical trials, biomedical literature, grant funding, FDA submissions, SEC filings, patent activity — pulled into the same enrichment pipeline.
Stack: ClinicalTrials.gov · PubMed · NIH RePORTER · FDA · SEC EDGAR · USPTO patent feedsYour brand language, palette, typography, and product taxonomy scraped and applied so deliverables feel native. This page is itself the example — Condor purple #613DF0 and navy #241348 lifted directly from condorsoftware.com.
Every claim cites the dossier and source it came from. Every artifact — code, data, prompts, dashboards — is yours to own from day 91 of any engagement. No model lock-in, no infrastructure lock-in.
Stack: Postgres / Supabase data layer · documented APIs · transferable IPWe map every active clinical-research PI globally working in your therapeutic adjacencies, walk each one to the independent academic lab they run, layer NIH grants + publications + biotech-founder signals on top, and ship a unified lab database. The point: catch the buyer at "first lab notebook," not "Series A press release." More on what this unlocks for Condor specifically immediately below.
Stack: ClinicalTrials.gov · NIH RePORTER · PubMed · SEC EDGAR · USPTO · Firecrawl-driven lab-page extraction · classification agentsMost of Condor's customers today were PhD students in someone's lab six years ago. Run our pipeline on Condor's therapeutic adjacencies and you get a refreshed, contact-attached, founder-signal-enriched database of every academic lab globally likely to spin out into your next biotech buyer — plus the academic medical centers running NIH- and industry-sponsored trials that need clinical-financial discipline today.
It would be unusual for a fintech-for-life-sciences platform to have this. We'd build it for Condor in Phase 1 of the Launch program below. Approximate scope after therapeutic-area filtering:
Launch is a 90-day program that ships a custom commercial intelligence + outbound system, built on the same SaaS principles Condor ships its product on. APIs at every layer. Audit trails end-to-end. Multi-tenant where it should be, single-tenant where it has to be. Owned by Condor on day 91.
Objective: Translate the Wave-C MI package into a working ICP model and per-persona buying scorecards across Condor's segments — emerging biotech, mid-market biotech, enterprise biopharma, MedTech, CRO partners.
Delivered: Versioned ICP schema (Postgres-backed), buying-persona definitions, multi-level enrichment + classification rules, deterministic account-fit scoring model, early addressable-market sizing, and the academic-to-biotech founder lab database from the section above.
You keep: Schema definitions, classification logic, scoring code, full audit log of inputs.
Stack: Postgres / Supabase · Clay (account & contact enrichment) · Sales Navigator (people graph) · custom classification agents · life-sciences API layer (ClinicalTrials.gov · PubMed · NIH RePORTER · FDA · SEC · USPTO)
Objective: Turn the ICP model into a live, enriched database of every account in Condor's addressable market — with the people, intent signals, and clinical/regulatory context attached.
Delivered: Enriched account universe (low thousands of accounts at minimum), per-account record (firmographics + technographics + clinical pipeline + funding + leadership), per-contact record with email/LinkedIn coverage, intent + trigger detection (new trials, FDA filings, fundraises, executive hires).
You keep: Full database export, query layer, refresh runbooks, every API key transferred to Condor-controlled accounts at handoff.
Stack: Clay (waterfall enrichment) · Sales Navigator · ClinicalTrials.gov · PubMed · NIH RePORTER · FDA · SEC EDGAR · USPTO · custom intent agents
Objective: Stand up a multi-channel outbound motion driven by an AI messaging agent that composes per-ICP, per-persona, per-account outreach grounded in the full enrichment record — and ship measured pipeline.
Delivered: Live email infrastructure (warmed domains, deliverability monitored), live LinkedIn motion, AI messaging agent with prompt + model + guardrails versioned in code, A/B framework, reply classifier, dashboards, a 30-day support tail.
You keep: Domain ownership, mailbox ownership, agent code + prompts, dashboards, reply data, every workflow.
Stack: EmailBison (email infra + warmup) · HeyReach (LinkedIn outbound) · custom messaging agent (Claude / Gemini / OpenAI under the hood) · reply classifier · Postgres dashboard layer
Objective: Hand the entire system to Condor's GTM org, clean.
Delivered: Documented architecture, runbooks, agent prompts, dashboards, all credentials moved to Condor-controlled vaults. Optional retainer for ongoing tuning if you want it.
You keep: Everything we built. No data lock-in. No model lock-in. No infrastructure lock-in.
Note: Condor-specific accounts (sending domains, mailbox seats, Clay seat, HeyReach workspace) transfer at handoff. BioCreative's firm-wide tooling (master Sales Navigator seat, master Clay workspace) stays with us — same model any SaaS-build engagement uses.
Code, data, prompts, dashboards, infrastructure — all transferred to Condor on day 91. We don't run an "AI black box" you keep paying us to operate. The Launch program is a build engagement; what we hand back is yours, the same way Condor hands customers a real platform they own outcomes on.
BioCreative Strategies is a strategic intelligence and GTM-build firm focused on life-sciences SaaS. We combine multi-agent research orchestration with a deterministic life-sciences API stack to deliver intelligence that is source-traced, auditable, and engineered to be owned by the company we build it for.
We lead with work product. This briefing is an example of what we deliver in Wave C (market intelligence) of our standard program. Launch is Waves D+E — the ICP/database/outbound system that sits on top of a Wave-C foundation.
30 minutes — open the briefing, walk the Launch architecture, decide whether a partnership makes sense.